Applications Open for Society for Translational Oncology Fellows’ Forum (STOFF)
Durham, NC (PRWEB) July 21, 2016 -- Applications will be accepted through August 31 for the Society for Translational Oncology Fellows’ Forum (STOFF) (formerly conducted by the Cancer Education Consortium). This 3-day intensive forum brings together 20-25 fellows and junior faculty (within 5 years of training completion) from leading medical oncology, surgical oncology, radiation oncology, and surgical subspecialty programs in the United States who are rising stars in translational cancer research.
Conducted under the auspices of the Society for Translational Oncology (STO), STOFF permanently relocated to Cary, North Carolina in 2015.
Co-chaired by Dr. Jeffrey Engelman (Novartis Institute for Biomedical Research) and Dr. Keith Flaherty (Massachusetts General Hospital/Harvard Medical School), the distinguished STOFF faculty includes researchers and educators from the National Cancer Institute (NCI), U.S. Food and Drug Administration (FDA), and leading U.S. cancer centers. STOFF has received national recognition for its focused and practical approach to preparing oncologists to conduct cancer drug research. Alumni total more than 375.
STOFF provides a forum for oncology fellows and junior faculty to interact with leaders in drug development and translational research. It promotes:
• Professional development
• Research, education, and the science of drug development in oncology
• Networking of oncology fellows and faculty
• Mentorship to guide career development for young oncologists
“Educating young oncologists in the field of clinical and translational research is an investment in the future and is likely to impact the quality of cancer patient care for years to come,” said Dr. Bruce A. Chabner (Massachusetts General Hospital/Harvard Medical School), who founded the course almost 20 years ago. “Bringing STOFF to North Carolina will allow STO to take advantage of the superb resources in cancer research and cancer clinical trials in the North Carolina scientific community.”
The relocation of STOFF to North Carolina, in proximity to the campus of SAS Institute (Cary, NC), provides a unique opportunity to introduce fellows to the Project Data Sphere® initiative, an innovative, web-based, library/laboratory with patient-level data from more than 25,000 clinical trial participants. Project Data Sphere, LLC, an independent initiative of the CEO Roundtable's Life Sciences Consortium, was established in concert with global analytics experts at SAS, which provides the basic software platform for much of the clinical trials effort internationally, and Members of the CEO Roundtable on Cancer (Cary, NC), a CEO-led non-profit whose mission is to eliminate cancer as a global, public health threat.
The broad-based curriculum covers a range of topics related to new drug development. Expert faculty will lead discussions and present important information regarding preclinical and clinical evaluation. The discussion will include a focus on validation of targets and biomarkers, and confirmation of mechanism of action and resistance in clinical trials. The discussion will also address racial and age-related disparities in clinical trials.
STOFF will be held December 8-11, in Cary, North Carolina, USA.
To submit an application, read the eligibility and application information here: http://sto-online.org/STO-Fellows-Forum-2016. For questions, send email to STOFF(at)sto-online.org.
# # #
About the Society for Translational Oncology
STO is a non-profit, tax exempt association whose mission is to speed the discovery and translation of important new treatments in the field of cancer medicine to the practice of global oncology. STO brings knowledge and strategies for critical new developments in cancer treatment to the practice of the community oncologist.
For more information, visit: http://www.sto-online.org.
For more information, contact:
Jen Homan, Program Manager, STO
(919) 433-0489
jen.homan(at)sto-online.org
Jen Homan, Society for Translational Oncology, +1 (919) 680-0011, [email protected]
Share this article